Menu Search
Equities

ADC Therapeutics SA

ADCT:NYQ

ADC Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.33
  • Today's Change0.12 / 3.74%
  • Shares traded1.89m
  • 1 Year change+333.59%
  • Beta1.5837
Data delayed at least 15 minutes, as of Sep 20 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ADC Therapeutics SA's revenues fell -66.86% from 209.91m to 69.56m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 157.13m to a larger loss of 240.05m.
Gross margin92.99%
Net profit margin-312.84%
Operating margin-206.87%
Return on assets-47.51%
Return on equity--
Return on investment-56.37%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ADC Therapeutics SA fell by 47.84m. Cash Flow from Financing totalled 73.88m or 106.21% of revenues. In addition the company used 118.69m for operations while cash used for investing totalled 3.22m.
Cash flow per share-2.43
Price/Cash flow per share--
Book value per share-1.36
Tangible book value per share-1.36
More ▼

Balance sheet in USDView more

ADC Therapeutics SA appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets while day-to-day operations are losing money. One plus is that there are enough liquid assets to satisfy current obligations, however, this situation is unsustainable over the long run. ADC Therapeutics SA has considerable financial risk.
Current ratio6.17
Quick ratio5.90
Total debt/total equity--
Total debt/total capital1.44
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.